List details

Basic info

Status Withdrawn
Details on the scope of restriction A derogation for the import and use in pharmaceutical products for the treatment of pulmonary diseases in entry 68 of Annex XVII: Perfluorooctanoic acid (PFOA), its salts and related substances.
Reason for restriction This use was not identified during the processing of the PFOA restriction, and the Commission requested ECHA to review the derogation request of AstraZeneca.

Intention timeline

Date of intention 2018-05-16
Expected date of submission 2018-06-20
Withdrawal date 2020-10-14
Latest update 2020-10-16

Support information

Reason for withdrawal After preparation, this report was processed for an opinion from RAC and SEAC via the procedure outlined in REACH Article 77(3)(c). Please refer to the dedicated Article 77(3)(c) pages on the ECHA website for details and related documents: RAC https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests SEAC https://echa.europa.eu/opinions-of-the-seac-adopted-under-specific-echa-s-executive-director-requests
Restriction report and annexes

Related substances

By adding any of the following substances to your watchlist, you would be monitoring this regulatory record and all possible new regulatory records related to that substance.

Related regulatory records

Add the related substance to your watchlist to monitor this regulatory record.